A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

This study is testing a new experimental cancer drug called DR-0202 in people with advanced or metastatic solid tumors — including breast, lung, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, stomach, bladder, and other cancers — that have stopped responding to standard treatments. **You may be eligible if...** - You have one of the listed cancer types that has spread or cannot be surgically removed - You have already tried at least 2 prior treatment lines and no standard options remain - Your cancer shows measurable tumors on imaging scans - Your general health and organ function meet the study requirements - You are willing to provide tumor tissue samples **You may NOT be eligible if...** - You had major surgery within 28 days before starting the study - You have not waited long enough since your last cancer treatment - You have serious or uncontrolled infections, autoimmune disease, or other major health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.